Cargando…

Signaling changes in the stem cell factor–AKT-S6 pathway in diagnostic AML samples are associated with disease relapse

Detalles Bibliográficos
Autores principales:	Kornblau, S M, Covey, T, Putta, S, Cohen, A, Woronicz, J, Fantl, W J, Gayko, U, Cesano, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255271/ https://www.ncbi.nlm.nih.gov/pubmed/22829109 http://dx.doi.org/10.1038/bcj.2010.2

Ejemplares similares

Functional Characterization of FLT3 Receptor Signaling Deregulation in Acute Myeloid Leukemia by Single Cell Network Profiling (SCNP)
por: Rosen, David B., et al.
Publicado: (2010)

Functional Pathway Analysis Using SCNP of FLT3 Receptor Pathway Deregulation in AML Provides Prognostic Information Independent from Mutational Status
por: Cesano, Alessandra, et al.
Publicado: (2013)

Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia
por: Rosen, David B., et al.
Publicado: (2010)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
por: Rosen, David B., et al.
Publicado: (2013)

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML
por: Oancea, Claudia, et al.
Publicado: (2014)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Gene Expression Profiles Associated with Pediatric Relapsed AML
por: Bachas, Costa, et al.
Publicado: (2015)

Bilateral Conjunctival Infiltration as an Extramedullary Relapse of AML
por: Mozaheb, Zahra, et al.
Publicado: (2018)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
por: Zeng, Zhihong, et al.
Publicado: (2016)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Thavayogarajah, T., et al.
Publicado: (2022)

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
por: Noviello, Maddalena, et al.
Publicado: (2019)

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
por: Nassereddine, Samah, et al.
Publicado: (2018)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023)

Association of Reactive Oxygen Species-Mediated Signal Transduction with In Vitro Apoptosis Sensitivity in Chronic Lymphocytic Leukemia B Cells
por: Palazzo, Adam L., et al.
Publicado: (2011)

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
por: Emdal, Kristina B., et al.
Publicado: (2022)

Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Malagola, Michele, et al.
Publicado: (2014)

Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO‐DB SHIP consortium
por: White, Tara, et al.
Publicado: (2022)

Relapsed or primary refractory AML: moving past MEC and FLAG-ida
por: Koenig, Kristin, et al.
Publicado: (2020)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

An agonist antibody prefers relapsed AML for induction of cells that kill each other
por: Yea, Kyungmoo, et al.
Publicado: (2019)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

An Atypical Presentation of Relapsing Polychondritis Manifesting As Acute Angle Closure
por: Cape, Hays, et al.
Publicado: (2023)

Optical Genome Mapping for Cytogenetic Diagnostics in AML
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2023)

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
por: Kong, Y, et al.
Publicado: (2015)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

Diffuse periostitis as the primary presenting radiological finding in an AML patient with disease relapse
por: Mushtaq, Raza, et al.
Publicado: (2018)

IDH1-mutated relapsed or refractory AML: current challenges and future prospects
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2019)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
por: Klement, Piroska, et al.
Publicado: (2022)

A new adult AML case with an extremely complex karyotype, remission and relapse combined with high hyperdiploidy of a normal chromosome set in secondary AML
por: Wafa, Abdulsamad, et al.
Publicado: (2018)

Emergence of an unrelated highly aberrant clone in an AML patient at relapse four months after peripheral blood stem cell transplantation
por: Kadam, Pratibha S., et al.
Publicado: (2007)

Loss of Mismatched HLA Detected in the Peripheral Blood of an AML Patient who Relapsed After Haploidentical Hematopoietic Stem Cell Transplantation
por: Park, Borae G., et al.
Publicado: (2015)

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
por: Sockel, Katja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oj8t72ac5ktcgprah43k9j1uho